Inhibitor of renal transporters OAT1 and OAT3; Antihepatitis agent as a substrate for intestinal PEPT1

Natural radical scavenger, inhibiting L-glutamate toxicity in neuronal hybridoma N18-RE-105 cells

Natural Inhibitor for Protein−Protein Interaction of the Homodimer of Proteasome Assembly Factor 3

Potent inhibitor of the proliferation of PC3 prostate carcinoma cells

Natural naphthyridine alkaloid

Novel Inhibitor of Jumonji AT-Rich Interactive Domain 1B (JARID1B) Histone Demethylase

Novel mitophagy inducer with therapeutic potential for Parkinson's disease, acting as light chain 3 (LC3) interactors, similar to cardiolipin or ceramide, triggering mitophagy via Pink1/Parkin

Novel fluorogenic yellow fluorescent dye for use in self-labeling tag systems

Novel anti-triple-negative breast cancer (anti-TNBC) agent with a high selectivity against BC cells over normal human cells, downregulating phosphatidylinositide 3-kinase (PI3K)/Akt pathway by suppressing protein-tyrosine phosphatase 1B (PTP1B) expression

Novel positive allosteric modulator of AMPA receptor

Novel potent JAK1/3 inhibitor, targeting JAK3 and JAK1 with IC 50 at 3nM and 5nM, respectively

Novel potent JAK1/2/3 inhibitor

Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket

Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket

Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine

Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine

Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine

Novel selective Jak2 inhibitor, demonstrating a time-dependent knock-down of pSTAT5, a downstream target of Jak2

Novel JAK1 inhibitor

Novel highly potent JAK1-selective inhibitor, exhibiting excellent selectivity over JAK2, JAK3, and TYK2 (IC 50 : JAK1 0.145 nM; JAK2 2.94 nM; JAK3 2.31 nM; TYK2 8.17 nM)

Novel potent and cleavable proteolysis targeting chimeric (PROTAC) for TrkC degradation in metastatic breast cancer cells

Novel potent noncleavable proteolysis targeting chimeric (PROTAC) for TrkC degradation in metastatic breast cancer cells

Novel WNT inhibitor, suppressing cytoplasmic and nuclear biochemical markers of WNT signaling in cultured cells, inhibiting recombinant TNKS activity, or WNT fatty acylation

Novel WNT inhibitor, suppressing cytoplasmic and nuclear biochemical markers of WNT signaling in cultured cells, inhibiting recombinant TNKS activity, or WNT fatty acylation

Novel, orally available soluble guanylate cyclase (sGC) stimulator with once-daily dosing potential for the treatment of cardiovascular diseases

Prodrug of QVO, being quickly converted to QVO in mice and rats following administration, ameliorating hyperglycemia, and suppressing hepatic gluconeogenesis and activating AMPK signaling pathway in the liver tissues

The first Ang IV-analogue being able to abolish IRAP-availability completely at the cell surface in vitro

Selective inhibitor of the funny channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium

First-in-class iodothyronine deiodinase type 3 (DIO3) inhibitor, demonstratig attenuated cell counts, induction in apoptosis, and a reduction in cell proliferation in DIO3-positive HGSOC cells (OVCAR3 and KURAMOCHI)

Novel highly potent, orally bioavailable hepatitis C virus (HCV) entry inhibitor